IP Library Granted Patent US 10,294,201
Granted Patent B2
US 10,294,201 · App. 15/895,685 · Granted May 21, 2019

Process for production of glycopyrronium tosylate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,294,201
App. No.
15/895,685
Granted
May 21, 2019
Kind
B2
Abstract

Provided herein are methods for the production of glycopyrronium tosylate and glycopyrronium tosylate compositions. Also provided herein are compositions useful in the production of glycopyrronium tosylate. Additionally provided herein are glycopyrronium tosylate compositions. Glycopyrronium tosylate is useful for the treatment of, among other conditions, hyperhidrosis.

Claims (44)

1. A method of producing purified glycopyrronium tosylate comprising:

purifying glycopyrronium tosylate by one or more crystallizations in an aqueous solvent to obtain a purified glycopyrronium tosylate, wherein the aqueous solvent consists essentially of water.

2. The method of claim 1 , wherein the aqueous solvent consists of water.

3. The method of claim 1 , wherein the glycopyrronium tosylate is purified by at least two crystallizations in the aqueous solvent.

4. The method of claim 1 , wherein the purified glycopyrronium tosylate is a mixture of threo-glycopyrronium tosylate and erythro-glycopyrronium tosylate, and the threo-glycopyrronium tosylate is at least 99% of the total glycopyrronium tosylate in the mixture and the erythro-glycopyrronium tosylate is less than 1% of the total glycopyrronium tosylate in the mixture.

5. The method of claim 4 , wherein the threo-glycopyrronium tosylate is at least 99.5% of the total glycopyrronium tosylate in the mixture and the erythro-glycopyrronium tosylate is less than 0.5% of the total glycopyrronium tosylate in the mixture.

6. The method of claim 4 , wherein the threo-glycopyrronium tosylate is at least 99.6% of the total glycopyrronium tosylate in the mixture and the erythro-glycopyrronium tosylate is less than 0.4% of the total glycopyrronium tosylate in the mixture.

7. The method of claim 1 , further comprising producing glycopyrronium tosylate by

contacting glycopyrrolate base with methyl tosylate to produce glycopyrronium tosylate:

wherein the glycopyrrolate base is contacted with a water-miscible organic solvent.

8. The method of claim 7 , wherein the water-miscible organic solvent is a water-miscible aldehyde, organic acid, ketone, nitrile, diol, alcohol, aminoalcohol, glycol, sulfoxide, ether, cyclic ether, cyclic diether, amine, polyol, or cyclic amine comprising from 1 to 6 carbon atoms.

9. The method of claim 7 , wherein the water-miscible organic solvent is acetone.

10. The method of claim 7 , wherein the reaction is conducted at a temperature selected over the range of 20° C. to 26° C.

11. The method of claim 7 , wherein the glycopyrronium tosylate is produced as a mixture of threo-glycopyrronium tosylate and erythro-glycopyrronium tosylate, and the threo-glycopyrronium tosylate is at least 95% of the total glycopyrronium tosylate in the mixture and the erythro-glycopyrronium tosylate is less than 5% of the total glycopyrronium tosylate in the mixture.

12. The method of claim 11 , wherein the threo-glycopyrronium tosylate is at least 96% of the total glycopyrronium tosylate in the mixture and the erythro-glycopyrronium tosylate is less than 4% of the total glycopyrronium tosylate in the mixture.

13. The method of claim 11 , wherein the threo-glycopyrronium tosylate is at least 97% of the total glycopyrronium tosylate in the mixture and erythro-glycopyrronium tosylate is less than 3% of the total glycopyrronium tosylate in the mixture.

14. The method of claim 7 , further comprising producing glycopyrrolate base by contacting a glycopyrrolate base, 5-nitroisophthalate salt with an inorganic base to form the glycopyrrolate base:

15. The method of claim 14 , wherein the inorganic base is aqueous sodium hydroxide.

16. The method of claim 14 , wherein the glycopyrrolate base, 5-nitroisophthalate salt, and inorganic base are contacted with a water-immiscible organic solvent.

17. The method of claim 16 , wherein the water-immiscible organic solvent is selected from the group consisting of benzene, n-butanol, carbon tetrachloride, chloroform, cyclohexane, ethylene chloride, heptane, hexane, pentane, toluene, trichloroethylene, and xylene.

18. The method of claim 16 , wherein the water-immiscible organic solvent is toluene.

19. The method of claim 14 , wherein the glycopyrrolate base is produced as a mixture of threo-glycopyrrolate base and erythro-glycopyrrolate base, and the threo-glycopyrrolate base is at least 95% of the total glycopyrrolate base produced and the erythro-glycopyrrolate base is less than 5% of the total glycopyrrolate base produced.

20. The method of claim 19 , wherein the threo-glycopyrrolate base is at least 96% of the total glycopyrrolate base produced and the erythro-glycopyrrolate base is less than 4% of the total glycopyrrolate base produced.

21. The method of claim 19 , wherein the threo-glycopyrrolate base is at least 97% of the total glycopyrrolate base produced and the erythro-glycopyrrolate base is less than 3% of the total glycopyrrolate base produced.

22. The method of claim 14 , further comprising producing glycopyrrolate base, 5-nitroisophthalate salt by contacting a glycopyrrolate base with 5-nitroisophthalic acid to form the glycopyrrolate base, 5-nitroisophthalate salt:

23. The method of claim 22 , wherein the glycopyrrolate base and 5-nitroisophthalic acid are contacted with methanol.

24. The method of claim 22 , wherein the contacting of a glycopyrrolate base with 5-nitroisophthalic acid is conducted at a temperature selected over the range of 20° C. to 26° C.

25. The method of claim 22 , further comprising producing glycopyrrolate base by contacting cyclopentylmandelic acid with 1-methylpyrrolidin-3-ol to form the glycopyrrolate base:

26. A method of producing glycopyrronium tosylate comprising:

(i) contacting cyclopentylmandelic acid with 1-methylpyrrolidin-3-ol to form glycopyrrolate base:

(ii) contacting the glycopyrrolate base with 5-nitroisophthalic acid to form glycopyrrolate base, 5-nitroisophthalate salt:

(iii) contacting the glycopyrrolate base, 5-nitroisophthalate salt with an inorganic base to form glycopyrrolate base:

(iv) contacting the glycopyrrolate base with methyl tosylate to produce glycopyrronium tosylate:

wherein the glycopyrrolate base is contacted with a water-miscible organic solvent;

and

(v) purifying the glycopyrronium tosylate obtained in step (iv) by one or more crystallizations in an aqueous solvent to obtain a purified glycopyrronium tosylate; wherein the aqueous solvent consists essentially of water.

27. The method of claim 26 , wherein the purified glycopyrronium tosylate of step (v) is a mixture of threo-glycopyrronium tosylate and erythro-glycopyrronium tosylate, and the threo-glycopyrronium tosylate is at least 99% of the total glycopyrronium tosylate in the mixture and the erythro-glycopyrronium tosylate is less than 1% of the total glycopyrronium tosylate in the mixture.

28. The method of claim 27 , wherein the threo-glycopyrronium tosylate is at least 99.5% of the total glycopyrronium tosylate in the mixture and the erythro-glycopyrronium tosylate is less than 0.5% of the total glycopyrronium tosylate in the mixture.

29. The method of claim 27 , wherein the threo-glycopyrronium tosylate is at least 99.6% of the total glycopyrronium tosylate in the mixture and the erythro-glycopyrronium tosylate is less than 0.4% of the total glycopyrronium tosylate in the mixture.

30. The method of claim 26 , wherein the step (v) is purifying the glycopyrronium tosylate obtained in step (iv) by at least two crystallizations in the aqueous solvent.

31. The method of claim 26 , wherein in step (v), wherein the aqueous solvent consists of water.

32. The method of claim 26 , wherein in step (iv) the water-miscible organic solvent is acetone.

33. The method of claim 26 , wherein in step (iii) the glycopyrrolate base, 5-nitroisophthalate salt is dissolved in water and contacted with toluene, and the inorganic base is aqueous sodium hydroxide.

34. The method of claim 26 , wherein in step (ii) the glycopyrrolate base is contacted with 5-nitroisophthalic acid in methanol.

Assignments (4)
SECURITY INTEREST Recorded Dec 28, 2023
From: JOURNEY MEDICAL CORPORATION; JG PHARMA, INC.
To: SWK FUNDING LLC
Reel/Frame 066157/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2021
From: DERMIRA, INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 056829/0767 →
RELEASE OF SECURITY INTEREST Recorded Feb 20, 2020
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: DERMIRA, INC.
Reel/Frame 051882/0260 →
SECURITY INTEREST Recorded Dec 7, 2018
From: DERMIRA, INC.
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Reel/Frame 047701/0465 →